Navigation Links
Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Date:12/7/2009

THOUSAND OAKS, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that its board of directors has authorized repurchases of up to an additional $5 billion in Amgen common stock. The company currently has approximately $1.2 billion remaining under its previous stock repurchase authorization. This new authorization reflects Amgen's confidence in its long-term prospects.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2008, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.


CONTACT:
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
10. Call for Applications: The Amgen Award for Science Teaching Excellence
11. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... you know that PhRMA member companies invested $65.5 billion in research ... medicines, generics and the supply chain account for 14 percent of ... this (7 percent)? Or that the United States ... in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health Management, LLC., ... Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of ... Health Management/Patient Engagement Solutions. , MAP was selected as a finalist for ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the world’s first all-diabetes ... pro squad as a stagiaire for the remainder of the 2017 season. One of ... 31st at the Tour of Utah. , “Every season we are excited to move ...
(Date:7/27/2017)... York, NY (PRWEB) , ... July 27, 2017 ... ... to President Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS ... The event kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , ...
(Date:7/26/2017)... , ... July 26, 2017 , ... Capillus, LLC has ... hereditary hair loss. The new Flexible Fitting Design offers a more comfortable, adaptable fit ... is delighted with the improvements to the home-use laser therapy caps intended to improve ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area roller derby leagues ... “Make ‘em Bleed,” the most widely attended series of blood drives in California, beginning July ... blood over the past 4 years -- enough to have helped to save up to ...
Breaking Medicine News(10 mins):